Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2022 Feb 1;79(2):141-148.
doi: 10.1001/jamaneurol.2021.4514.

Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis

Ronda Lun  1   2 , Shan Dhaliwal  1 , Gabriele Zitikyte  1   3 , Danielle Carole Roy  1 , Brian Hutton  1   3 , Dar Dowlatshahi  1   2   3
Affiliations
Comparative Study

Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis

Ronda Lun et al. JAMA Neurol. .

Abstract

Importance: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA). However, there is emerging evidence for the use of ticagrelor and aspirin, and the 2 DAPT regimens have not been compared directly.

Objective: To compare ticagrelor and aspirin with clopidogrel and aspirin in patients with acute minor ischemic stroke or TIA in the prevention of recurrent strokes or death.

Data sources: MEDLINE, Embase, and Cochrane from database inception until February 2021.

Study selection: Randomized clinical trials that enrolled adults with acute minor ischemic stroke or TIA and provided the mentioned interventions within 72 hours of symptom onset, with a minimum follow-up of 30 days.

Data extraction and synthesis: PRISMA guidelines for network meta-analyses were followed. Two reviewers independently extracted data and appraised risk of bias. Fixed-effects models were fit using a bayesian approach to network meta-analysis. Between-group comparisons were estimated using hazard ratios (HRs) with 95% credible intervals (95% CrIs). Surface under the cumulative rank curve plots were produced.

Main outcomes and measures: The primary outcome was a composite of recurrent stroke or death up to 90 days. Secondary outcomes include major bleeding, mortality, adverse events, and functional disability. A sensitivity analysis was performed at 30 days for the primary outcome.

Results: A total of 4014 citations were screened; 5 randomized clinical trials were included. Data from 22 098 patients were analyzed, including 5517 in the clopidogrel and aspirin arm, 5859 in the ticagrelor and aspirin arm, and 10 722 in the aspirin arm. Both clopidogrel and aspirin (HR, 0.74; 95% CrI, 0.65-0.84) and ticagrelor and aspirin (HR, 0.79; 95% CrI, 0.68-0.91) were superior to aspirin in the prevention of recurrent stroke and death. There was no statistically significant difference between clopidogrel and aspirin compared with ticagrelor and aspirin (HR, 0.94; 95% CrI, 0.78-1.13). Both DAPT regimens had higher rates of major hemorrhage than aspirin alone. Clopidogrel and aspirin was associated with a decreased risk of functional disability compared with aspirin alone (HR, 0.82; 95% CrI, 0.74-0.91) and ticagrelor and aspirin (HR, 0.85; 95% CrI, 0.75-0.97).

Conclusions and relevance: DAPT combining aspirin with either ticagrelor or clopidogrel was superior to aspirin alone, but there was no statistically significant difference found between the 2 regimens for the primary outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hutton reported honoraria from Eversana Inc outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. PRISMA Flow Diagram
Figure 2.
Figure 2.. Network Diagram of the Total Number of Patients Analyzed in Each Treatment Arm for All 90-Day Outcomes, Excluding Functional Disability
ASA indicates acetylsalicylic acid (aspirin).
See this image and copyright information in PMC

References

    1. Hao Q, Tampi M, O’Donnell M, Foroutan F, Siemieniuk RA, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ. 2018;363:k5108. doi:10.1136/bmj.k5108 - DOI - PMC - PubMed
    1. Khare S. Risk factors of transient ischemic attack: an overview. J Midlife Health. 2016;7(1):2-7. doi:10.4103/0976-7800.179166 - DOI - PMC - PubMed
    1. Amarenco P, Lavallée PC, Monteiro Tavares L, et al. ; TIAregistry.org Investigators . Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med. 2018;378(23):2182-2190. doi:10.1056/NEJMoa1802712 - DOI - PubMed
    1. Zhang C, Zhao X, Wang C, et al. ; Chinese IntraCranial AtheroSclerosis (CICAS) Study Group . Prediction factors of recurrent ischemic events in one year after minor stroke. PLoS One. 2015;10(3):e0120105. doi:10.1371/journal.pone.0120105 - DOI - PMC - PubMed
    1. Coutts SB, Hill MD, Campos CR, et al. ; VISION study group . Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients? Stroke. 2008;39(9):2461-2466. doi:10.1161/STROKEAHA.107.513234 - DOI - PubMed

MeSH terms